Shares of Natco Pharma gained over 3% in a weak market today after the company received a favourable judgement from Delhi High Court in a patent infringement case of Chlorantraniliprole (CTPR) process.┬аNatco Pharma stock┬аrose 3.51% to Rs 599.05┬аtoday against the previous close of Rs 578.75┬аon BSE.
Shares of┬аNatco Pharma┬аare trading┬аhigher than the 5-day and 20-day moving averages but lower than 50-day, 100-day and 200-day moving averages.┬а┬аThey opened at Rs 586.15 against the previous close of Rs 578.75 on BSE.┬а┬а┬аThe stock has lost 29.75% in a year and fallen 35.38% in 2022.┬а┬аIn a month, the stock is down 6.6%.┬а┬а┬а┬а
Total 0.16 lakh shares of the firm changed hands amounting to a turnover of Rs 95.17 lakh in the afternoon session. Market cap of the firm rose to Rs 10,660 crore on BSE.┬аThe stock hit a 52-week high of Rs 942.15 on January 17, 2022 and a 52-week low of Rs 559 on November 30, 2022 on BSE.┬а
The drug maker said that the double bench of the High Court of Delhi has dismissed an appeal filed by FMC Corporation, FMC Singapore and FMC India and has upheld prima facie the Judgement of the single judge that the company’s Chlorantraniliprole (CTPR) process does not infringe FMC’s Indian Patent 298645.
Also Read:┬аShare Market News Live: Sensex falls over 300 points, Nifty tests 18,600; Hindalco, Tata Steel, JSW Steel top drags
Patent IN 298645 covers a process to prepare Chlorantraniliprole (CTPR) that is set to expire on December 6, 2025.
CTPR technical process has insecticides used across a wide range of crops for pest management.
Natco Pharma is a vertically integrated, research and development (R&D)-focused pharmaceutical company. The company is engaged in the development, manufacture and commercialisation of complex pharmaceuticals catering to niche therapeutic areas. The company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the rest of the world, as well as active pharmaceutical ingredients (APIs).
